Views & Analysis Why AI and blockchain are the solutions to developing orphan... We are in the midst of a significant shift in pharmaceutical drug development, with many leading companies focusing increasingly on orphan drugs targeted at small niche markets.
Views & Analysis Why blockchain is a dream come true for pharma researchers Researchers tend to have a genuine scientific curiosity and desire to make the world better with their discoveries.
Views & Analysis Four steps to building an innovation culture in pharma The quest for innovation is a major driving force in pharma.
Views & Analysis How blockchain will revolutionise clinical trials The risky and unpredictable nature of the clinical trial process is a major driver of high costs for pharmaceutical drugs.
Views & Analysis To unlock innovation, pharma needs to be honest about failur... Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock inn
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.